Janssen publishes the latest clinical data invokana ® to improve renal function in diabetic patients

Source: Janssen Pharmaceutical companies of Johnson & Johnson announced today an additional analysis of the landmark canvas project, showing that invokana? (canagliflozin) can improve the renal prognosis of type 2 diabetic patients with high-risk cardiovascular disease These data were presented at the 2018 National Kidney Foundation spring clinical meeting in Austin, Texas Diabetes is an increasingly serious global epidemic As of 2015, 400 million adults worldwide were affected by diabetes Diabetic nephropathy is an important complication of diabetes, which has become one of the most common causes of end-stage renal disease Because of its complex metabolic disorder, once it develops to the end stage, it is often more difficult to treat than other kidney diseases Therefore, timely prevention and treatment of diabetic nephropathy is of great significance Canagliflozin is a once daily oral diabetes drug, which belongs to a new drug of SGLT2 inhibitor These drugs can reduce the blood glucose level of the body by blocking the reabsorption of blood glucose by the kidney and increasing the excretion of blood glucose in the urine The canvas project is the longest and most extensive trial focusing on cardiovascular efficacy among all SGLT2 inhibitors It is also the first project to evaluate the efficacy, safety and durability of canagliflozin in more than 10000 type 2 diabetic patients with a history of cardiovascular disease or at least two cardiovascular risk factors In the new analysis, canagliflozin reduced the ratio of urinary albumin to creatinine (UACR), a key biomarker of chronic kidney disease In patients with renal function retention and reduction, the glomerular filtration rate (EGFR) decreased by 17% and 23% from baseline, respectively (P heterogeneity = 0.01) Canagliflozin resulted in a 47% reduction in relative risk (HR 0.53, 95% CI 0.39-0.73, P heterogeneity = 0.28) and a 24% reduction in risk (HR 0.76, 95% CI 0.49-1.17, P heterogeneity = 0.28) in patients with reduced renal function at a predetermined composite end point (EGFR reduction of 40%, end-stage renal disease or renal death) Similar results have also been observed in the compound focus of doubling serum creatinine instead of decreasing EGFR by 40% No new adverse events were observed in the study "Diabetic nephropathy is still the most common cause of end-stage renal disease worldwide, which highlights the need to further explore the potential renal protective effects of SGLT2 inhibitors," said George, professor and director of the comprehensive hypertension center at the University of Chicago School of medicine "The new analysis adds a lot of evidence that canagliflozin potentially improves kidney outcomes in millions of patients with type 2 diabetes, a benefit that can be observed in patients with preserved and reduced renal function," Dr Bakris said "Although about one-third of diabetic patients have diabetic nephropathy, there is no significant progress in treatment," said James F "We are encouraged that canagliflozin may provide much-needed benefits to patients with diabetic nephropathy, and look forward to further enhancing this insight in credence, the first dedicated SGLT2 inhibitor trial and full patient recruitment, to assess renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy," Dr list said We look forward to seeing more positive data of this new type 2 diabetes drug in the future, and bringing new therapies to the majority of diabetic patients as soon as possible.